Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold?

Abstract excerpt

ABSTRACT: Menin inhibitors constitute a novel class of agents targeting the underlying biology of nucleophosmin (NPM1) mutant and KMT2A (formerly known as MLL1) rearranged (KMT2Ar) acute leukemias. KMT2Ar acute leukemias constitute 5% to 10% of acute leukemias, and NPM1 mutations are identified in 30% of newly diagnosed acute myeloid leukemias (AMLs). In preclinical AML models, small molecule inhibitors of the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Leukemia, Myeloid, Acute
• Share to Mutation
• Share to Nucleophosmin